oligonucleotide-therapeutics
(2)
Guofeng Cheng’s second act is a $360 million race from lab bench to launch
After a dozen years helping antiviral programs move through Gilead, the scientist-founder built AusperBio around one stubborn idea: make the molecule do more work. Seven years later, the company is preparing for the harder passage from clinical promise to commercial reality.
AusperBio
AusperBio is a clinical-stage biopharmaceutical company operating in the United States and China that develops antisense oligonucleotide (ASO) therapies aimed at a functional cure for chronic hepatitis B. Built on its proprietary Med-Oligo ASO platform and targeted delivery technology, its lead candidate AHB-137 is an unconjugated ASO advancing into Phase III trials in China, with early data showing a 30% functional cure rate in a subset of patients. Founded in 2019 and headquartered in San Mateo, California, the company has raised over $200 million to date.